VolitionRX
Open
$1.41
Prev. Close
$1.41
High
$1.41
Low
$1.39
Market Snapshot
$10.94M
-0.4
-0.31
$1.23M
75
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 75 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 75 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Recently from Cashu
VolitionRx Secures €2 Million Funding to Enhance Diagnostic Solutions and Market Accessibility
VolitionRx Secures New Funding to Advance Innovative Diagnostic Solutions VolitionRx Limited, a multinational epigenetics company, announces the successful raise of €2.0 million (approximately $2.3 mi…
VolitionRX Showcases Innovative Lung Cancer Detection Findings at European Conference
VolitionRX Unveils Promising Findings for Lung Cancer Management at ELCC VolitionRX Limited, an epigenetics company specializing in innovative cancer detection techniques, showcases groundbreaking res…
VolitionRX Advances Liquid Biopsy Technology for Precision Cancer Detection and Monitoring
VolitionRX Revolutionizes Liquid Biopsy Technology for Early Cancer Detection VolitionRx Limited, an epigenetics company based in Henderson, Nevada, is at the forefront of transforming cancer diagnost…
VolitionRX Advances Liquid Biopsy Technology for Early Cancer Detection and Monitoring
VolitionRX Pioneers Advancement in Liquid Biopsy Technology for Cancer Detection VolitionRx Limited, a leading epigenetics firm based in Henderson, Nevada, makes substantial progress in liquid biopsy…